



HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

Big Data (analytics) to enable better and faster treatment for Patients with Hematologic Malignancies.

Partnering Session at the 23rd Congress of EHA

Invitation to partner

Date Saturday, 16th June 2018

Time frame 16:15-17:15 hrs.

Venue Room K11, Stockholm International Fairs, Sweden

It's all about Big Data in Hematology. Your Big Data!

Big Data will have an impact on health and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases.

HARMONY: Ready to collect data and deliver outcomes.

Let's connect

- Participate in our **Interactive Session**: Open for Clinicians, Researchers, Data Providers, and Patient and nurses' organizations. We will update you on HARMONY's latest steps and achievements.
June 16 | Room K2 | 14:45-16:15

- Join us at our **Partnering session**: Open for organizations interested to become a data provider. We will inform you about the opportunities and the guidelines.
June 16 | Room K11 | 16:15–17:15

- Visit us at the exhibition! You can find us in **booth** nr. **1284**.





Session Program

Feeding the HARMONY Platform: Guidelines for Data Providers

Objectives and format

With a round-table Q&A format, this session aims to be an informal reception especially intended for potential data providers and organisations that are already in the process of becoming HARMONY Associated Members. The members of the HARMONY Steering Committee will answer questions about data sharing, anonymization, and all the concerns that participants may have regarding our project.

For the past months, we have contacted more than one hundred European organisations, assisting them in the process of becoming HARMONY Associated Members. When answering the technical, legal, and ethical questions we receive, we have found out that most of the issues encountered by our Associated Members are very similar. With this open session, we search to clarify those recurrent topics that might be of interest for our potential Associated Members, and speed up the data sharing process in the field of hematological malignancies across Europe.

Speakers

- Jesús María Hernández Rivas – HARMONY Coordinator, IBSAL, Spain;
- Lars Bullinger – HARMONY Work Package 2 Leader, Charité, Germany;
- Michel van Speybroeck – HARMONY Work Package 3 Leader, Janssen, Belgium;
- John Butler – HARMONY Work Package Leader 8, Bayer, Germany.

Topics

Even though this session will remain open to any topics the attendants may want to raise, the following items will be addressed by HARMONY task leaders and Partners present:

- Issues and solutions regarding legal agreements: Associated Member Engagement Framework, and Associated Member Data Sharing Agreement;
- Data privacy and protection: HARMONY compliance with GDPR;
- De-facto Anonymization.



About the HARMONY Alliance:

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology

The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 53 public and private partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs).

The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Approach:

- Collect, share, and harmonize Big Data from high-quality multidisciplinary sources.
- Assess and integrate a large amount of molecular data to better understand outcomes in specific hematological malignancies.
- Generate evidence to encourage healthcare systems to pay particular attention to the value of healthcare and to improve outcomes.
- Facilitate drug development pipelines and accelerate the “bench-to-bedside” process in drug development.

Focus:

- Multiple myeloma (MM), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Myelodysplastic Syndromes (MDS), and Pediatric Hematologic Malignancies.

Budget:

- 40 M€

Duration:

- 2017 - 2021

Contact:

- **HARMONY Coordination Office**
Institute of BioMedical Research of Salamanca (IBSAL), Salamanca, Spain
Phone: +34 616 222 324 | E-mail: harmonyoffice@ibsal.es
- **HARMONY Communications Office**
European Hematology Association (EHA), The Hague, the Netherlands
Phone: +31 70 302 0099 | E-mail: communications@harmony-alliance.eu

www.harmony-alliance.eu | [@harmonyNetEU](https://twitter.com/harmonyNetEU)

